Washington (AFP) – The US Food and Drug Administration’s approval process for a controversial drug used to treat Alzheimer’s was “rife with irregularities,” a congressional report said Thursday. An 18-month investigation into the FDA’s green-lighting of the drug, Aduhelm, also criticized its manufacturer, biotechnology company Biogen. The Cambridge, Massachusetts-based Biogen set an “unjustifiably high price” for Aduhelm of $56,000 a year to “make history” with the first drug approved in decades to treat Alzheimer’s, the report said. Aduhelm received “accelerated approval” from the FDA in June…